Salvage therapy in patients with advanced non-small cell lung cancer

Pablo M. Bedano, Nasser H. Hanna

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations

Abstract

Patients with advanced non-small cell lung cancer continue to have a poor prognosis; most die from the disease within 1 year. Chemotherapy is beneficial for some patients in the first-line metastatic setting. Three agents, namely docetaxel, pemetrexed, and erlotinib, are approved by the United States Food and Drug Administration as treatment in the second-line setting. In this article, we examine the data supporting the use of these agents in the second-line setting and review data from other completed trials. Lastly, we propose strategies to advance the treatment of patients with non-small cell lung cancer.

Original languageEnglish (US)
Pages (from-to)582-587
Number of pages6
JournalJournal of Thoracic Oncology
Volume1
Issue number6
DOIs
StatePublished - Jul 1 2006

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Salvage therapy in patients with advanced non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this